Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters 2004-02, Vol.14 (4), p.909-912
Main Authors: ZHICAI WU, FRALEY, Mark E, BIN SHI, SEPP-LORENZINO, Laura, THOMAS, Kenneth A, BILODEAU, Mark T, KAUFMAN, Mildred L, TASBER, Edward S, BALITZA, Adrienne E, HARTMAN, George D, COLL, Kathleen E, RICKERT, Keith, SHIPMAN, Jennifer
Format: Article
Language:English
Subjects:
Biological and medical sciences
Drug Design
Enzyme Inhibitors - chemical synthesis
Enzyme Inhibitors - pharmacology
Humans
Medical sciences
Miscellaneous
Molecular Structure
Pharmacology. Drug treatments
Pyridines - chemical synthesis
Pyridines - pharmacology
Solubility
Structure-Activity Relationship
Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2003.12.007